The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes
Open accessAbstract
BACKGROUND: No targeted immunotherapies reverse type 1 diabetes in humans. However, in a rodent model of type 1 diabetes, Bacillus Calmette-Guerin (BCG) reverses disease by restoring insulin secretion. Specifically, it stimulates innate immunity by inducing the host to produce tumor necrosis factor (TNF), which, in turn, kills disease-causing autoimmune cells and restores pancreatic beta-cell function through regeneration. METHODOLOGY/PRINCIPAL FINDINGS: Translating these findings to humans, we administered BCG, a generic vaccine, in a proof-of-principle, double-blind, placebo-controlled trial of adults with long-term type 1 diabetes (mean: 15.3 years) at one clinical center in North America. Six subjects were randomly assigned to BCG or placebo and compared to self, healthy paired controls (n = 6) or reference subjects with (n = 57) or without (n = 16) type 1 diabetes, depending upon the outcome measure. We monitored weekly blood samples for 20 weeks for insulin-autoreactive T cells, regulatory T cells (Tregs), glutamic acid decarboxylase (GAD) and other autoantibodies, and C-peptide, a marker of insulin secretion. BCG-treated patients and one placebo-treated patient who, after enrollment, unexpectedly developed acute Epstein-Barr virus infection, a known TNF inducer, exclusively showed increases in dead insulin-autoreactive T cells and induction of Tregs. C-peptide levels (pmol/L) significantly rose transiently in two BCG-treated subjects (means: 3.49 pmol/L [95% CI 2.95-3.8], 2.57 [95% CI 1.65-3.49]) and the EBV-infected subject (3.16 [95% CI 2.54-3.69]) vs.1.65 [95% CI 1.55-3.2] in reference diabetic subjects. BCG-treated subjects each had more than 50% of their C-peptide values above the 95(th) percentile of the reference subjects. The EBV-infected subject had 18% of C-peptide values above this level. CONCLUSIONS/SIGNIFICANCE: We conclude that BCG treatment or EBV infection transiently modified the autoimmunity that underlies type 1 diabetes by stimulating the host innate immune response. This suggests that BCG or other stimulators of host innate immunity may have value in the treatment of long-term diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00607230.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Braghi, S., Bonifacio, E., Secchi, A., Di Carlo, V, Pozza, G., & Bosi, E. (2000) · Diabetes · doi:10.2337/diabetes.49.2.218 · Cited by 90 · cited 1×
“Altered GAD autoantibody levels have been documented to decrease after re-exposure of the immune system to childhood BCG vaccinations and acutely increase or decrease after islet transplantation although the clinical significance is unknown [20–22].”
Background
Cited by
Kleinnijenhuis, J., Quintin, J., Preijers, F., Benn, C. S., Joosten, L. A. B., Jacobs, C., van Loenhout, J., Xavier, R. J., Aaby, P., van der Meer, J. W. M., et al. (2014) · Journal of Innate Immunity · doi:10.1159/000355628 · Cited by 620
Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications
Yang, S., Wang, J., Brand, D. D., & Zheng, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00784 · Cited by 410
BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design
Covián, C., Fernández-Fierro, A., Retamal-Díaz, A., Díaz, F. E., Vasquez, A. E., Lay, M. K., Riedel, C. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02806 · Cited by 328
Low levels of C‐peptide have clinical significance for established Type 1 diabetes
Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold, P., Burger, D., Zheng, H., & Faustman, D. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12850 · Cited by 131
Self-citationCombination immunotherapy for type 1 diabetes
Bone, R. N., & Evans-Molina, C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0878-z · Cited by 41
Metadata
- Authors
- Faustman, D. L., Wang, L., Okubo, Y., Burger, D., Ban, L., Man, G., Zheng, H., Schoenfeld, D., Pompei, R., Avruch, J., & Nathan, D. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-08
- Volume
- 7
- Issue
- 8
- Pages
- e41756
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2116291006
- Cited by
- 168
- References
- 2
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes. https://app.cochat.ai/papers/10.1371/journal.pone.0041756
- The paper
- Faustman, D. L., Wang, L., Okubo, Y., Burger, D., Ban, L., Man, G., Zheng, H., Schoenfeld, D., Pompei, R., Avruch, J., & Nathan, D. M. (2012). Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes. PLoS ONE. https://doi.org/10.1371/journal.pone.0041756
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.